Allogene Therapeutics, Inc.
General ticker "ALLO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $427.5M (TTM average)
Allogene Therapeutics, Inc. follows the US Stock Market performance with the rate: 30.8%.
Estimated limits based on current volatility of 2.8%: low 1.71$, high 1.81$
Factors to consider:
- Total employees count: 150 (-34.5%) as of 2025
- Top business risk factors: Capital raising failure, Construction delays, Regulatory and compliance, Labor/talent shortage/retention, Cybersecurity threats
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.93$, 2.60$]
- 2026-12-31 to 2027-12-31 estimated range: [0.99$, 2.69$]
Financial Metrics affecting the ALLO estimates:
- Positive: with PPE of -1.6 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Positive: 69.38 < Shareholder equity ratio, % of 70.34 <= 81.92
- Positive: Investing cash flow per share per price, % of 31.35 > 2.08
- Positive: Inventory ratio change, % of 0 <= 0
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0.35 <= 0.75
Short-term ALLO quotes
Long-term ALLO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.10MM | $0.02MM | $0.00MM |
| Operating Expenses | $327.83MM | $273.22MM | $209.31MM |
| Operating Income | $-327.74MM | $-273.20MM | $-209.31MM |
| Non-Operating Income | $0.47MM | $16.05MM | $18.43MM |
| Interest Expense | $0.00MM | $0.18MM | $1.07MM |
| R&D Expense | $242.91MM | $192.30MM | $150.15MM |
| Income(Loss) | $-327.26MM | $-257.15MM | $-190.89MM |
| Taxes | $0.00MM | $0.44MM | $0.00MM |
| Net Income(Loss)* | $-327.26MM | $-257.59MM | $-190.89MM |
| Stockholders Equity | $512.23MM | $422.18MM | $292.54MM |
| Assets | $642.84MM | $548.71MM | $415.90MM |
| Operating Cash Flow | $-237.73MM | $-200.30MM | $-149.25MM |
| Capital expenditure | $1.52MM | $0.69MM | $0.39MM |
| Investing Cash Flow | $163.29MM | $75.69MM | $95.56MM |
| Financing Cash Flow | $95.69MM | $116.67MM | $30.16MM |
| Earnings Per Share** | $-2.09 | $-1.32 | $-0.87 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.